Related Experiment Video
Updated: Jun 27, 2025
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Abstract:
There is intense interest in identifying compounds that selectively kill senescent cells, termed senolytics, for ameliorating age-related comorbidities. However, screening for senolytic compounds currently relies on primary cells or cell lines where senescence is induced in vitro. Given the complexity of senescent cells across tissues and diseases, this approach may not target the senescent cells that develop under specific conditions in vivo. In this issue of the JCI, Lee et al. describe a pipeline for high-throughput drug screening of senolytic compounds where senescence was induced in vivo and identify the HSP90 inhibitor XL888 as a candidate senolytic to treat idiopathic pulmonary fibrosis.
Insights
Researchers developed a new method to find senolytic drugs that kill senescent cells. This approach, using in vivo induced senescence, identified XL888 as a potential treatment for idiopathic pulmonary fibrosis.
Area of Science:
- Cellular senescence
- Drug discovery
- Age-related diseases
Background:
- Senescent cells contribute to age-related diseases.
- Current senolytic drug screening uses in vitro induced senescence, which may not reflect in vivo conditions.
- Developing senolytics that target in vivo senescent cells is crucial.
Purpose of the Study:
- To establish a high-throughput drug screening pipeline for senolytic compounds using in vivo induced senescence.
- To identify novel senolytic compounds effective against specific in vivo senescent cell populations.
- To evaluate candidate senolytics for treating age-related diseases like idiopathic pulmonary fibrosis.
Main Methods:
- Development of a high-throughput screening pipeline for senolytic compounds.
- Induction of senescence in vivo.
- Screening of compounds using the developed pipeline.
- Identification of HSP90 inhibitor XL888 as a candidate senolytic.
Main Results:
- A novel pipeline for high-throughput screening of senolytics was established.
- Senescence was successfully induced in vivo.
- The HSP90 inhibitor XL888 was identified as a promising senolytic candidate.
- XL888 shows potential for treating idiopathic pulmonary fibrosis.
Conclusions:
- The developed in vivo senescence screening pipeline offers a more relevant approach for identifying senolytics.
- XL888 is a potential senolytic drug for idiopathic pulmonary fibrosis.
- This study paves the way for discovering targeted senolytics for various age-related conditions.
